Background: Data regarding the involvement of the pancreas during the course of inflammatory bowel disease (IBD) are scarce and conflicting. Aim: To assess the frequency of benign pancreatic diseases, that is, acute pancreatitis, chronic pancreatitis (CP), and autoimmune pancreatitis (AIP), in a population with IBD. Methods: A search for patients with IBD who presented at our hospital between January 2006 and January 2015 with a diagnosis of IBD was carried out. Patients: A total of 5,242 patients with IBD were included in this study (2,838 males, 54.1%, and 2,404 females, 45.9%, mean age 43.7 years, range 18-101 years). Of these 5,242 patients, 3,201 (61.1%) had Crohn's disease and 2,041 (38.9%) had ulcerative colitis (UC). Results: Thirteen patients developed benign pancreatic diseases (0.2%). Eight patients had acute pancreatitis (0.2%; 4 in the Crohn's disease group and 4 in the UC group), 3 had CP (0.1%, 2 in the Crohn's disease group and 1 in the UC group), 2 had AIP (0.04%), all in the group of diffuse UC (p = 0.321). Conclusions: The frequency of benign pancreatic disease was not high in patients with IBD and was probably similar to that seen in the general population.

Keywords:
Acute pancreatitis, Autoimmune pancreatitis, Chronic pancreatitis, Inflammatory bowel disease
1.
Vavricka SR, Schoepfer A, Scharl M, et al: Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1982-1992.
2.
Harbord M, Annese V, Vavricka SR, et al: The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016;10:239-254.
3.
Toda N, Akahane M, Kiryu S, Matsubara Y, Yamaji Y, Okamoto M, Minagawa N, Ohgi K, Komatsu Y, Yahagi N, Yoshida H, Kawabe T, Ohtomo K, Omata M: Pancreas duct abnormalities in patients with ulcerative colitis: a magnetic resonance pancreatography study. Inflamm Bowel Dis 2005;11:903-908.
4.
Park SH, Kim D, Ye BD, et al: The characteristics of ulcerative colitis associated with autoimmune pancreatitis. J Clin Gastroenterol 2013;47:520-525.
5.
Ueki T, Kawamoto K, Otsuka Y, et al: Prevalence and clinicopathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease. Pancreas 2015;44:434-440.
6.
Roque Ramos L, DiMaio CJ, Sachar DB, Atreja A, Colombel JF, Torres J: Autoimmune pancreatitis and inflammatory bowel disease: case series and review of the literature. Dig Liver Dis 2016;48:893-898.
7.
Pezzilli R, Zerbi A, Di Carlo V, Bassi C, Delle Fave GF: Practical guidelines for acute pancreatitis. Pancreatology 2010;10:523-535.
8.
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS: Classification of acute pancreatitis - 2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013;62:102-111.
9.
Whitcomb DC, Frulloni L, Garg P, Greer JB, Schneider A, Yadav D, Shimosegawa T: Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. Pancreatology 2016;16:218-224.
10.
Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, Kim MH, Klöppel G, Lerch MM, Löhr M, Notohara K, Okazaki K, Schneider A, Zhang L: International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas 2011;40:352-358.
11.
Bardhan KD, Simmonds N, Royston C, Dhar A, Edwards CM; Rotherham IBD Database Users Group: A United Kingdom inflammatory bowel disease database: making the effort worthwhile. J Crohns Colitis 2010;4:405-412.
12.
Antonini F, Pezzilli R, Angelelli L, Macarri G: Pancreatic disorders in inflammatory bowel disease. World J Gastrointest Pathophysiol 2016;7:276-282.
13.
Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, Klugmann T, Kruis W, Siegmund B, Helwig U, Weismüller J, Drabik A, Stallmach A: Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases - a prospective study on incidence and severity. J Crohns Colitis 2016;10:61-68.
14.
Arai Y, Arihiro S, Ide D, Odagi I, Itagaki M, Komoike N, Nakao Y, Takakura K, Saruta M, Matsuoka M, Kato T, Tajiri H: Acute pancreatitis due to pH-dependent mesalazine that occurred in the course of ulcerative colitis. Case Rep Gastroenterol 2011;5:610-616.
15.
Teich N, Bokemeyer B, Mohl W, Walldorf J, Bruns T, Schmidt C, Stallmach A: Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD. Gut 2016;pii:gutjnl-2016-313138.
16.
Seyrig JA, Jian R, Modigliani R, Golfain D, Florent C, Messing B, Bitoun A: Idiopathic pancreatitis associated with inflammatory bowel disease. Dig Dis Sci 1985;30:1121-1126.
17.
Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ: Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis 2005;11:1080-1084.
18.
Barthet M, Hastier P, Bernard JP, Bordes G, Frederick J, Allio S, Mambrini P, Saint-Paul MC, Delmont JP, Salducci J, et al: Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol 1999;94:2141-2148.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.